Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore, Singapore.
Pediatr Allergy Immunol. 2020 Jan;31(1):7-18. doi: 10.1111/pai.13127. Epub 2019 Oct 9.
Atopic dermatitis (AD) is a chronic inflammatory skin disease mainly affecting children, which has no definitive curative therapy apart from natural outgrowing. AD is persistent in 30%-40% of children. Epithelial barrier dysfunction in AD is a significant risk factor for the development of epicutaneous food sensitization, food allergy, and other allergic disorders. There is evidence that prophylactic emollient applications from birth may be useful for primary prevention of AD, but biomarkers are needed to guide cost-effective targeted therapy for high-risk individuals. In established early-onset AD, secondary preventive strategies are needed to attenuate progression to other allergic disorders such as food allergy, asthma, and allergic rhinitis (the atopic march). This review aims to describe the mechanisms underpinning the development of epicutaneous sensitization to food allergens and progression to clinical food allergy; summarize current evidence for interventions to halt the progression from AD to food sensitization and clinical food allergy; and highlight unmet needs and directions for future research.
特应性皮炎(AD)是一种主要影响儿童的慢性炎症性皮肤病,除了自然消退外,尚无明确的根治方法。AD 在 30%-40%的儿童中持续存在。AD 患者的上皮屏障功能障碍是发生表皮食物致敏、食物过敏和其他过敏疾病的重要危险因素。有证据表明,从出生开始预防性使用保湿剂可能有助于预防 AD,但需要生物标志物来指导针对高危人群的具有成本效益的靶向治疗。在已确诊的早发性 AD 中,需要采取二级预防策略来减轻向食物过敏、哮喘和过敏性鼻炎(特应性进行曲)等其他过敏疾病的进展。本综述旨在描述引发表皮食物过敏原致敏和向临床食物过敏发展的机制;总结目前关于干预措施以阻止 AD 向食物致敏和临床食物过敏发展的证据;并强调未满足的需求和未来研究的方向。